Evidence map›Paper›PMID 33077656›Full record

ArticleAntimicrobial agents and chemotherapy2020

Chloroquine Potentiates Primaquine Activity against Active and Latent Hepatic Plasmodia

Laurent Dembélé, Jean-François Franetich, Valérie Soulard, Nadia Amanzougaghene, Shahin Tajeri, Teun Bousema, Geert-Jan van Gemert, Roger Le Grand, Nathalie Dereuddre-Bosquet, J Kevin Baird and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Safety and Efficacy of Tafenoquine forTherapeutics and clinical risk management · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 5 countries.

Laurent DembéléSorbonne Université, INSERM, CNRS, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France.ORCID 0000-0001-9087-8439
Jean-François FranetichSorbonne Université, INSERM, CNRS, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France.
Valérie SoulardSorbonne Université, INSERM, CNRS, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France.
Nadia AmanzougagheneSorbonne Université, INSERM, CNRS, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France.
Shahin TajeriSorbonne Université, INSERM, CNRS, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France.
Teun BousemaDepartment of Medical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.ORCID 0000-0003-2666-094X
Geert-Jan van GemertDepartment of Medical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Roger Le GrandUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematalogical and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France.
Nathalie Dereuddre-BosquetUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematalogical and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France.
J Kevin BairdEijkman-Oxford Clinical Research Unit, Jakarta, Indonesia kbaird@eocru.org.ORCID 0000-0002-2170-300X
Dominique Mazier *Sorbonne Université, INSERM, CNRS, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France.
Georges Snounou *Sorbonne Université, INSERM, CNRS, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France.
Centre National de la Recherche Scientifique · FRInserm · FRRadboud University Nijmegen · NLEijkman Institute for Molecular Biology · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For a long while, 8-aminoquinoline compounds have been the only therapeutic agents against latent hepatic malaria parasites. These have poor activity against the blood-stage plasmodia causing acute malaria and must be used in conjunction with partner blood schizontocidal agents. We examined the impacts of one such agent, chloroquine, upon the activity of primaquine, an 8-aminoquinoline, against hepatic stages of

Indexed as

AntimalarialsMalariaPlasmodiumAnimalsChloroquineHumansPrimaquineAntimalarialsChloroquinePrimaquinechemotherapychloroquinehepatic parasiteslatent infectionmalariapotentiationprimaquine

Identifiers

PMID33077656
PMCPMC7927800
OpenAlexW3093185156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.